1st Optimal Real Customer Outcomes: An Evidence-Based Review

What Is 1st Optimal and How Does It Work?

1st Optimal positions itself as a concierge medicine practice specializing in performance and longevity protocols for adults seeking optimization beyond standard primary care. The clinic operates on a direct-pay model, bypassing insurance networks entirely.

Concierge medicine has grown rapidly in the United States. A 2023 survey published in the Journal of General Internal Medicine estimated that roughly 1.5% of practicing U.S. physicians now operate in direct primary care or concierge arrangements, with patient panels typically capped at 200 to 600 individuals compared to the 2,000+ panels common in traditional practice [1]. This smaller panel size allows longer consultations and more frequent follow-up. Whether that translates to better clinical outcomes depends on what is prescribed and how it is monitored.

1st Optimal's reported workflow follows a pattern common to performance medicine clinics: comprehensive blood panels, provider consultation, personalized treatment protocols, and ongoing lab monitoring every 8 to 12 weeks. The specific therapies prescribed vary by patient, but customer reviews consistently mention testosterone optimization, peptide protocols, and metabolic health interventions. The brand does not publish its formulary publicly, so the assessment below draws on patient-reported experiences cross-referenced with clinical evidence for each therapy class.

Testosterone Replacement: What the Evidence Actually Shows

Customer reviews of 1st Optimal frequently reference testosterone replacement therapy as a core offering. TRT is one of the most well-studied interventions in the performance medicine space, which makes it possible to evaluate expected outcomes with precision.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, remains the largest cardiovascular safety trial for testosterone therapy in hypogonadal men aged 45 to 80. The trial found that transdermal testosterone did not increase the incidence of major adverse cardiovascular events compared to placebo (hazard ratio 0.73; 95% CI 0.52 to 1.03) over a mean follow-up of 33 months [2]. This addressed a longstanding safety concern that had discouraged many clinicians from prescribing TRT.

For symptomatic outcomes, the Testosterone Trials (TTrials, N=790) demonstrated that 12 months of testosterone gel in men aged 65 and older with low testosterone produced statistically significant improvements in sexual function, walking distance, and mood compared to placebo [3]. The sexual function domain showed the largest effect. Physical function improvements were modest, and vitality gains were not statistically significant. These results set a realistic benchmark: TRT reliably improves some symptoms, but it is not a wholesale performance enhancer in men with borderline-low levels.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy only for men with unequivocally low serum testosterone (<300 ng/dL on two morning samples) and consistent symptoms [4]. Clinics prescribing testosterone to men with levels of 400 to 500 ng/dL for "optimization" are operating outside guideline recommendations. Customers evaluating 1st Optimal or any similar clinic should verify whether their pre-treatment levels actually meet diagnostic criteria for hypogonadism.

Peptide Therapy Protocols: Strong Claims, Mixed Evidence

Peptide therapy is a major selling point across concierge longevity clinics, and 1st Optimal is no exception. Customer reports mention BPC-157, CJC-1295/Ipamorelin combinations, and occasionally thymosin beta-4. The evidence base for these compounds varies dramatically.

BPC-157 (Body Protection Compound-157) has shown wound-healing and anti-inflammatory effects in rodent models, with studies demonstrating accelerated tendon, ligament, and muscle repair in rats [5]. Zero randomized controlled trials in humans have been completed as of May 2026. The FDA issued a warning letter in 2023 regarding compounded BPC-157 products, noting that the peptide has never received FDA approval for any indication and that compounding pharmacies cannot legally produce it under sections 503A or 503B of the FD&C Act without an approved drug application [6].

CJC-1295 combined with Ipamorelin is used in performance clinics to stimulate growth hormone secretion. A small study (N=21) published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 increased mean GH levels by 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold over 7 days, with effects sustained for up to 2 weeks after a single dose [7]. The clinical significance of this GH elevation for body composition or recovery in otherwise healthy adults remains unestablished in controlled trials.

Patients considering peptide protocols from any clinic should understand a direct point: most peptides used in performance medicine lack the human trial data that TRT and GLP-1 agonists have accumulated over decades. Positive anecdotes from clinic customers do not substitute for randomized evidence, and the placebo response rate in performance and wellness interventions routinely exceeds 30% [8].

GLP-1 Agonists in Performance and Longevity Protocols

Some 1st Optimal customers report being prescribed GLP-1 receptor agonists for metabolic optimization, even outside traditional obesity or type 2 diabetes indications. This reflects a broader trend in concierge medicine.

The evidence for GLP-1 agonists in weight management is substantial. In STEP-1 (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [9]. SURMOUNT-1 (N=2,539) demonstrated that tirzepatide at the highest dose (15 mg) produced 22.5% mean weight loss at 72 weeks versus 2.4% with placebo [10]. These are among the largest treatment effects ever recorded for anti-obesity medications in registration trials.

Beyond weight loss, SELECT (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, independent of diabetes status [11]. This trial shifted the clinical framing of GLP-1 agonists from "weight loss drugs" to cardiometabolic risk-reduction agents.

For performance-oriented patients with a BMI of 25 to 29 who do not meet traditional obesity criteria, the evidence is thinner. STEP-5 showed durable weight loss at 104 weeks, but all major GLP-1 trials enrolled participants with BMI ≥27 (with comorbidity) or ≥30 [12]. Using these medications in leaner individuals for "optimization" represents off-label use without trial-level evidence of benefit or safety in that population.

How to Evaluate Customer Reviews of Any Concierge Clinic

1st Optimal customer testimonials are largely positive across social media and review platforms. This pattern is common among direct-pay clinics and deserves careful interpretation rather than face-value acceptance.

Selection bias operates powerfully here. Patients who pay $200 to $500 per month out of pocket are already more motivated, more adherent, and more health-conscious than the average population. The "healthy user effect" is well-documented in epidemiology: people who choose to engage in health behaviors differ systematically from those who do not, in ways that independently predict better outcomes [13]. A concierge clinic patient who also sleeps 8 hours, trains 4 days per week, and eats a calorie-controlled diet may attribute their improvements to the prescription protocol when lifestyle factors explain much of the change.

Confirmation bias is another factor. When someone invests significant money in a medical protocol, they are psychologically motivated to perceive improvement. This is not dishonesty. It is a well-characterized cognitive pattern that placebo-controlled trials exist specifically to control for.

The most informative customer reviews will include specific lab values before and after treatment: total testosterone, free testosterone, hemoglobin A1c, lipid panels, inflammatory markers. Reviews reporting only subjective improvements ("I feel amazing") without objective data provide minimal signal about protocol effectiveness. Ask for numbers. Before-and-after labs are the minimum evidentiary standard that separates a useful review from a testimonial.

1st Optimal vs. Alternatives: What Matters in Choosing a Clinic

The concierge performance medicine market includes dozens of competitors: Marek Health, Defy Medical, Peter Uncaged MD, and various local optimization clinics. Differentiating between them requires asking specific questions rather than comparing marketing copy.

Three factors determine clinical quality in this space. First, does the clinic require baseline labs before prescribing, and do they use CLIA-certified laboratories? Any clinic prescribing testosterone without confirming hypogonadism on at least two separate morning blood draws is cutting a diagnostic corner that the Endocrine Society explicitly warns against [4].

Second, what is the monitoring cadence? The American Urological Association recommends measuring hematocrit 3 to 6 months after initiating TRT, with ongoing monitoring every 6 to 12 months, because testosterone therapy can cause polycythemia [14]. Clinics that prescribe and then schedule annual follow-ups only are below the standard of care.

Third, does the clinic acknowledge the limits of its therapies? A provider who presents BPC-157 as "clinically proven" is misrepresenting the evidence base. A provider who says "animal data is promising but we lack human RCTs" is being accurate and honest. The second provider is the one you should trust. Transparency about uncertainty is a marker of clinical integrity.

1st Optimal's position in this field appears comparable to other mid-tier concierge clinics: telehealth-based, direct-pay, with a mix of evidence-backed and evidence-limited therapies. Without published outcome data, clinical registries, or third-party audits, it is not possible to rank them above or below competitors with any objectivity.

Cost Considerations and Value Assessment

Concierge performance medicine is expensive relative to conventional care. Customer reports suggest 1st Optimal's costs include a monthly membership or consultation fee plus medication costs, which are typically sourced from compounding pharmacies.

For context, testosterone cypionate 200 mg/mL (10 mL vial) costs approximately $30 to $80 at retail pharmacies with a GoodRx coupon. Through a concierge clinic using a compounding pharmacy, the same medication often costs $100 to $200 per month. The markup covers compounding customization, provider oversight, and pharmacy profit margins.

GLP-1 agonists represent the largest cost variable. Branded semaglutide (Wegovy) carries a list price of approximately $1,349 per month, though compounded semaglutide from 503B pharmacies has been available at $200 to $500 per month [15]. The FDA's position on compounded semaglutide has been contested in litigation, and availability may shift depending on regulatory outcomes.

Patients should calculate the total annualized cost of a concierge protocol, including membership fees, lab work, medications, and any required in-person visits, and compare that against what their insurance would cover for the same FDA-approved medications through a conventional provider. For patients with commercial insurance that covers TRT and GLP-1 agonists, the concierge model may cost 3x to 5x more than the insured route. The trade-off is access speed, longer consultation time, and protocol customization.

Lab Monitoring: The Non-Negotiable Standard

Regardless of which clinic a patient selects, adequate laboratory monitoring is the single most important safety measure in hormone and peptide therapy. This is not optional.

For patients on TRT, the Endocrine Society recommends measuring total testosterone, hematocrit, and PSA at 3 to 6 months and then annually [4]. The AUA adds liver function tests at baseline and hemoglobin monitoring to detect polycythemia, which occurs in roughly 5% to 18% of men on TRT depending on formulation and dose [14].

For patients on GLP-1 agonists, monitoring should include renal function (semaglutide is renally excreted), amylase and lipase if pancreatitis symptoms develop, and thyroid function given the FDA boxed warning for medullary thyroid carcinoma risk based on rodent data [16]. The SUSTAIN and STEP programs did not show increased thyroid cancer risk in humans during trial periods of up to 104 weeks, but post-marketing surveillance continues.

Any clinic that prescribes these medications without structured lab monitoring at defined intervals is creating preventable risk. Customers reviewing 1st Optimal or any competitor should confirm the monitoring schedule in writing before starting treatment.

What "Longevity Medicine" Actually Means in 2026

The term "longevity medicine" appears frequently in 1st Optimal's positioning. It is worth defining what this term means in evidence-based practice versus in marketing.

The interventions with the strongest evidence for extending human healthspan are not exotic. They are caloric moderation, regular resistance training, cardiovascular exercise, sleep optimization, blood pressure control, statin therapy for qualifying patients, and smoking cessation [17]. Metformin is being tested in the TAME trial (Targeting Aging with Metformin, N=3,000 planned) as a potential geroprotective agent, but that trial has not yet reported primary results [18].

Rapamycin, NAD+ precursors, and senolytics are actively studied in preclinical and early-phase human trials for aging-related indications. None has sufficient evidence to recommend in routine clinical practice. The American Federation for Aging Research has been cautious in distinguishing between "longevity research" and "longevity prescribing," noting that the field remains pre-regulatory for most novel interventions [18].

A concierge clinic that prescribes FDA-approved medications (testosterone, semaglutide, metformin) while monitoring patients carefully can deliver real value. A clinic that charges premium prices for unproven compounds while calling the package "longevity medicine" is selling a brand identity more than an evidence-based protocol. Customers should evaluate which category their experience falls into based on what is actually prescribed.

Patients starting or evaluating any performance medicine protocol should request their complete lab results in writing, confirm that all prescribed medications have either FDA approval or a clear evidence-based rationale for off-label use, and verify the monitoring schedule before committing to a recurring payment plan.